首页> 外文期刊>Kidney international. >Role for [ldquo]uremic toxin[rdquo] in the progressive loss of intact nephrons in chronic renal failure
【24h】

Role for [ldquo]uremic toxin[rdquo] in the progressive loss of intact nephrons in chronic renal failure

机译:“尿毒症毒素”在慢性肾衰竭中完整肾单位进行性丧失的作用

获取原文
获取外文期刊封面目录资料

摘要

Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. We studied the effect on the progression of glomerular sclerosis of two different experimental maneuvers, peritoneal dialysis and oral adsorbent, which remove circulating substances in different fashions Munich-Wistar rats with established glomerular sclerosis, verified by renal biopsy analysis at seven weeks after subtotal nephrectomy, were treated for four weeks with either peritoneal dialysis (PD) or oral charcoal adsorbent (AST-120). Treatment was initiated at eight weeks. Rats were paired in treatment and control groups according to the similarity in the degree of sclerosis determined at biopsy with a minimum of 50 glomeruli analyzed. Systolic blood pressure and BUN and creatinine clearance, measured at seven to eight weeks, were not different among groups. In Group 2 rats, PD was performed with 1.5% dextrose for eight one-hour cycles, six days per week, while Group 1 control rats had zero indwelling time of the dialysate. Group 4 rats received AST-120, an oral adsorbent charcoal, mixed 5% by weight with standard rat chow and given ad libitum from 8 to 12 weeks after subtotal nephrectomy, while control Group 3 rats received only rat chow. Whole kidney GFR at 12 weeks was significantly higher in Group 2 PD versus Group 1 control (0.50 0.08 vs. 0.30 0.05 ml/min, P < 0.05). There was no statistical difference for BUN and whole kidney creatinine or inulin clearance in Group 4 AST-120 treated versus Group 3 control rats. Light microscopic studies in autopsy specimens revealed that both PD and AST-120 attenuated progression of glomerular sclerosis. Thus, at autopsy, the sclerosis index averaged 1.78 0.21 versus 1.30 0.19 in Group 1 control and Group 2 PD, respectively (P < 0.05), and 1.42 0.16 versus 0.99 0.13 in Group 3 control and Group 4 AST-120 treated rats, respectively (P < 0.05). Since the dialysis replaces primarily the filtration function of the nephrons removed at the onset of the study, the present observations support the possibility that the biologically-active circulating substances, or so-called "uremic toxins", are involved in the advancement of glomerular sclerosis and are ultrafiltrable in nature.
机译:“尿毒症毒素”在慢性肾衰竭中完整肾单位的逐渐丧失中的作用。我们研究了两种不同的实验操作(腹膜透析和口服吸附剂)对肾小球硬化进展的影响,这两种方法以不同的方式清除了已建立肾小球硬化的慕尼黑-维斯塔大鼠,并在全肾切除术后7周通过肾脏活检分析证实了这一点,用腹膜透析(PD)或口服木炭吸附剂(AST-120)治疗四周。在八周时开始治疗。根据活检确定的硬化程度的相似性,将大鼠分为治疗组和对照组,并分析至少50个肾小球。各组在7至8周测量的收缩压,BUN和肌酐清除率无差异。在第2组大鼠中,PD用1.5%的葡萄糖进行8个一小时循环,每周六天,而第1组对照大鼠的透析液滞留时间为零。第4组大鼠接受口服吸附剂活性炭AST-120,其与标准大鼠食物混合5%(重量),并在全肾切除后的8至12周内随意给予,而对照组3组仅接受大鼠食物。第2组PD组第12周的全肾GFR显着高于第1组对照组(0.50 0.08对0.30 0.05 ml / min,P <0.05)。在第4组AST-120治疗组与第3组对照大鼠中,BUN和全肾肌酐或菊粉清除率无统计学差异。尸检标本的光学显微镜研究表明,PD和AST-120均可减弱肾小球硬化的进展。因此,在尸检时,在第1组对照和第2组PD中,硬化指数分别平均为1.78 0.21对1.30 0.19(P <0.05),在第3组对照和第4组AST-120处理的大鼠中分别为1.42 0.16对0.99 0.13。 (P <0.05)。由于透析主要取代了研究开始时去除的肾单位的过滤功能,因此本观察结果支持了生物活性循环物质或所谓的“尿毒症毒素”参与肾小球硬化的发展的可能性。并且本质上是超滤的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号